trial · primary record
Visugromab RDE (recommended dose for expansion)
Metastatic Non-Squamous Non-Small Cell Lung Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 131 |
| Primary completion | 2031-10-01 |
| Primary endpoint | Objective Response Rate (ORR) |
| Registry ID | NCT07246863 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:30.452Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07246863
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.